Histone Acetyltransferase Inhibitor

Histone Acetyltransferase Inhibitors (148):

Cat. No.	Nom du produit	Effet	Pureté

HY-RS07083

KAT7 Human Pre-designed siRNA Set A	Inhibitor
KAT7 Human Pre-designed siRNA Set A contains three designed siRNAs for KAT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-117617

CAY10669	Inhibitor	99.9%
CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC₅₀ of 662 μM. CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells.

HY-125969

Rtt109 inhibitor 1	Inhibitor	98.00%
Rtt109 inhibitor 1 (Compound 1) is an inhibitor for histone acetyltransferase Rtt109 through a tight binding, uncompetitive system. Rtt109 inhibitor 1 exhibits antifungal activity through acetylation at H3K56 site.

HY-145954

NAT2-IN-1	Inhibitor	99.0%
NAT2-IN-1 (APA) is an inhibitor of agent metabolic enzyme N-acetyltransferase 2 (NAT2). NAT2-IN-1 can selectively kill slow NAT2 cells.

HY-124892A

Acetylethylcholine mustard hydrochloride	Inhibitor	99.61%
Acetylethylcholine mustard hydrochloride (Acetyl-AF64) is an inhibitor of choline acetyl-transferase that reduces the contraction frequency of the myotubes by inhibiting the synthesis of acetylethylcholine (Ach) with the half-maximal inhibitory concentration (IC₅₀) of 1.22 mM. Acetylethylcholine mustard hydrochloride is an irreversible ligand for the high affinity choline transport system. Acetylethylcholine mustard hydrochloride is also a cholinotoxin. Acetylethylcholine mustard hydrochloride is a precursor for ethylcholine mustard aziridinium ion.

HY-107455R

A-485 (Standard)	Inhibitor	99.84%
A-485 (Standard) is the analytical standard of A-485 (HY-107455). This product is intended for research and analytical applications. A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.

HY-134621

P300-IN-1	Inhibitor
P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor.

HY-W013274A

CPTH2 hydrochloride	Inhibitor
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B).

HY-143443

DS17701585	Inhibitor
DS17701585 (Compound 11) is a highly selective, orally active EP300 and CBP inhibitor with IC₅₀ values of 0.040, 0.15, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. DS17701585 can be used for cancer research.

HY-139861

CBP/p300-IN-14	Inhibitor
CBP/p300-IN-14 is a potent inhibitor of CBP/EP300 (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27).

HY-143442

CBP/p300-IN-18	Inhibitor
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively.

HY-128367

Ep300/CREBBP-IN-4	Inhibitor
Ep300/CREBBP-IN-4 (Example 56) is a potent Ep300 and CREBBP inhibitor with IC₅₀s of 0.024 and 0.064 μM, respectively. Ep300/CREBBP-IN-4 can be used for the research of cancer.

HY-183992

CZL-149	Inhibitor
CZL-149 is an orally active dual BET and p300/CBP bromodomains inhibitor with IC₅₀s of 13 nM and 10.5 nM for BED4 BD1 and p300, respectively. CZL-149 reduces c-Myc and H3K27Ac levels. CZL-149 has good drug-like properties and metabolic characteristics, as well as good safety. CZL-149 can be used for the study of multiple myeloma.

HY-155229

CBP/p300-IN-21	Inhibitor
CBP/p300-IN-21 (Compound 5d) is a selective CBP/p300 inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice.

HY-143339

CBP/p300-IN-15	Inhibitor
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research.

HY-139804

CTK7A	Inhibitor
CTK7A is a curcumin derivative with anticancer activity by inhibiting the HAT activity of p300 and reducing the autoacetylation of p300, thereby affecting its interaction with HIF-1α. The inhibition of CTK7A leads to decreased HIF-1α accumulation and activity, which can be used for cancer research.

HY-177044

KAT6A/KAT7-IN-2	Inhibitor
KAT6A/KAT7-IN-2 is a KAT6A and KAT7 inhibitor. KAT6A/KAT7-IN-2 has IC₅₀ values of both ≤ 1 nM for KAT6A and KAT7. KAT6A/KAT7-IN-2 can inhibit the acetylation of H3K14 and H3K23. KAT6A/KAT7-IN-2 also inhibits tumor cell proliferation. KAT6A/KAT7-IN-2 can be used in the study of cancer.

HY-181957

KB528	Inhibitor
KB528 is a p300/CBP histone acetyltransferase (KAT) inhibitor with low nM IC₅₀ values against human p300 and CBP, and exhibits selectivity over other KAT family members. KB528 modulates the IRF4 transcriptional network, downregulates the expression of IRF4, MYC, CAV2 and IGLL5, and reduces the protein level of IKZF3. KB528 potently induces apoptosis in multiple myeloma cells. KB528 is applicable to research related to multiple myeloma.

HY-128364

Ep300/CREBBP-IN-3	Inhibitor
Ep300/CREBBP-IN-3 (Example 61) is a potent Ep300 and CREBBP inhibitor with IC₅₀s of 0.056 and 0.095 μM, respectively. Ep300/CREBBP-IN-3 can be used for the research of cancer.

HY-146445

P300 bromodomain-IN-1	Inhibitor
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells.

Nom
Email *

	Sorry, but the email address you supplied was invalid.